Elsevier

Journal of Infection

Volume 58, Issue 4, April 2009, Pages 315-316
Journal of Infection

Letter to the editor
Different bile concentration of micafungin and itraconazole in a patient with candidal cholecystitis

https://doi.org/10.1016/j.jinf.2009.02.004Get rights and content

Section snippets

Conflict of interest

None of the authors declare a conflict of interest.

References (9)

There are more references available in the full text version of this article.

Cited by (5)

  • Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations

    2015, International Journal of Antimicrobial Agents
    Citation Excerpt :

    According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the MIC breakpoint for fluconazole susceptibility is ≤2 mg/L for C. albicans, C. krusei and C. tropicalis and ≤0.002 mg/L for C. glabrata. Caspofungin reached a biliary concentration of 1.0 mg/L after a 70 mg infusion, and micafungin reached 1.9 mg/L after administration of 150 mg [22,23]. The EUCAST breakpoint for susceptibility is ≤0.016 mg/L for C. albicans and ≤0.03 mg/L for C. glabrata.

  • Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole

    2013, Clinica Chimica Acta
    Citation Excerpt :

    There is little literature on the urinary excretion of ITZ metabolites. ITZ is also excreted in bile; however, its concentration in bile was reported to be lower than 10 μg/l [14]. Prolonged ITZ therapy has been reported to lead to acquired resistance by Aspergillus fumigatus [15].

View full text